Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Public ClinicalTrials.gov record NCT03925727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye
Study identification
- NCT ID
- NCT03925727
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Industry
- Enrollment
- 623 participants
Conditions and interventions
Conditions
Interventions
- Tavilermide ophthalmic solution Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2019
- Primary completion
- Jun 10, 2020
- Completion
- Jun 10, 2020
- Last update posted
- Apr 4, 2023
2019 – 2020
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tavilermide Investigational Site | Phoenix | Arizona | 85032 | — |
| Tavilermide Investigational Site | Los Angeles | California | 90013 | — |
| Tavilermide Investigational Site | Newport Beach | California | 92663 | — |
| Tavilermide Investigational Site | Fort Collins | Colorado | 80528 | — |
| Tavilermide Investigational Site | Littleton | Colorado | 80120 | — |
| Tavilermide Investigational Site | Boynton Beach | Florida | 33437 | — |
| Tavilermide Investigational Site | Bradenton | Florida | 34209 | — |
| Tavilermide Investigational Site | Coral Springs | Florida | 33067 | — |
| Tavilermide Investigational Site | Ocala | Florida | 34474 | — |
| Tavilermide Investigational Site | Indianapolis | Indiana | 46290 | — |
| Tavilermide Investigational Site | Sioux City | Iowa | 51104 | — |
| Tavilermide Investigational Site | Lexington | Kentucky | 40509 | — |
| Tavilermide Investigational Site | Louisville | Kentucky | 40206 | — |
| Tavilermide Investigational Site | St Louis | Missouri | 63131 | — |
| Tavilermide Investigational Site | Shelby | North Carolina | 28150 | — |
| Tavilermide Investigational Site | Cincinnati | Ohio | 45236 | — |
| Tavilermide Investigational Site | Mason | Ohio | 45040 | — |
| Tavilermide Investigational Site | Rapid City | South Dakota | 57701 | — |
| Tavilermide Investigational Site | Maryville | Tennessee | 37803 | — |
| Tavilermide Investigational Site | Nashville | Tennessee | 37205 | — |
| Tavilermide Investigational Site | San Antonio | Texas | 78248 | — |
| Tavilermide Investigational Site | Kenosha | Wisconsin | 53142 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03925727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03925727 live on ClinicalTrials.gov.